Published in Vaccine on May 11, 2012
Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS One (2014) 1.39
Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A (2013) 1.24
Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther (2012) 1.02
Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine (2013) 0.95
Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine (2013) 0.91
Adjuvants for vaccines to drugs of abuse and addiction. Vaccine (2014) 0.87
Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem (2013) 0.86
Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One (2014) 0.85
Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. Mol Pharm (2014) 0.85
Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines. Anal Bioanal Chem (2014) 0.84
Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods (2014) 0.83
Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats. Br J Pharmacol (2013) 0.82
Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. Bioconjug Chem (2015) 0.80
Synthesis and immunological effects of heroin vaccines. Org Biomol Chem (2014) 0.78
The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol (2015) 0.77
Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. Semin Fetal Neonatal Med (2012) 0.76
Biologics to treat substance use disorders: Current status and new directions. Hum Vaccin Immunother (2016) 0.75
Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend (2005) 6.91
Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend (2006) 4.24
Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry (2009) 3.61
Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther (2011) 2.33
Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature (1974) 1.81
The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev (2011) 1.76
Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry (2010) 1.75
Prescription pain medication dependence. Am J Psychiatry (2011) 1.65
How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med (2011) 1.49
A vaccine strategy that induces protective immunity against heroin. J Med Chem (2011) 1.47
Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol (1997) 1.38
A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine (2006) 1.35
Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J (2011) 1.28
Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl) (2001) 1.19
Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol (2011) 1.18
Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin (2009) 1.15
An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther (2012) 1.13
Evidence for active immunity to morphine in mice. Science (1972) 1.08
Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo. J Pharmacol Exp Ther (2009) 1.03
Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol (2011) 1.01
Influence of active and passive immunity on the disposition of dihydromorphine-H3. Life Sci (1974) 0.86
Vaccines move forward against a range of addictions. Nat Med (2011) 0.86
Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody. J Mol Biol (2011) 0.81
Embryonic stem cell lines derived from human blastocysts. Science (1998) 65.53
Morphological and antigenic relationships between viruses (rotaviruses) from acute gastroenteritis of children, calves, piglets, mice, and foals. Infect Immun (1976) 4.55
Sequence analysis of termini of conjugative transposon Tn916. J Bacteriol (1988) 3.22
Genetic organization of the bacterial conjugative transposon Tn916. J Bacteriol (1988) 3.18
Mutation of a new sodium channel gene, Scn8a, in the mouse mutant 'motor endplate disease'. Nat Genet (1995) 2.99
Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther (1991) 2.96
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
Taking health status into account when setting capitation rates: a comparison of risk-adjustment methods. JAMA (1996) 2.78
Long term follow up of women after hysterectomy with a history of pre-invasive cancer of the cervix. Br J Obstet Gynaecol (1992) 2.72
Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol (1985) 2.53
International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev (1996) 2.43
Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J Cell Biol (1988) 2.41
Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother (1973) 2.33
Anxiety caused by abnormal result of cervical smear test: a controlled trial. BMJ (1990) 2.22
Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci (1987) 2.19
Classification of macroalgae as fuel and its thermochemical behaviour. Bioresour Technol (2008) 2.15
Patients' attitudes to the provision of medical care from a health centre. J R Coll Gen Pract (1974) 2.14
Preferences and practices among renters regarding smoking restrictions in apartment buildings. Tob Control (2003) 2.13
Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse. Cell (1997) 2.13
Demonstration and solubilization of antigens expressed primarily on the surfaces of Candida albicans germ tubes. Infect Immun (1984) 2.13
The isolation of reovirus-like agents (rota-viruses) from acute gastroenteritis of piglets. J Med Microbiol (1976) 2.12
Diagnosing bacterial respiratory infection by bronchoalveolar lavage. J Infect Dis (1987) 2.07
PEX19 binds multiple peroxisomal membrane proteins, is predominantly cytoplasmic, and is required for peroxisome membrane synthesis. J Cell Biol (2000) 2.07
Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp Clin Psychopharmacol (1999) 2.01
The development of a risk-adjusted capitation payment system: the Maryland Medicaid model. J Ambul Care Manage (1998) 1.86
Transformation of Rickettsia prowazekii to rifampin resistance. J Bacteriol (1998) 1.85
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem (1980) 1.80
Thio reduction of human 2 -macroglobulin. The subunit structure. Biochem J (1972) 1.79
Mitochondrial DNA polymorphism in Candida albicans. J Infect Dis (1987) 1.79
The outcome of pregnancy after cone biopsy of the cervix: a case-control study. Br J Obstet Gynaecol (1979) 1.75
Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther (1988) 1.73
Enhancing effect of bacterial endotoxins on bone marrow cells in the immune response to SRBC. J Immunol (1972) 1.69
Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS (1990) 1.61
Analysis of cell wall extracts of Candida albicans by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot techniques. Infect Immun (1986) 1.58
Appropriateness of acute medical admissions and length of stay. J R Coll Physicians Lond (1998) 1.55
Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther (1997) 1.52
Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect Immun (1980) 1.48
Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos (2005) 1.47
Isolation, purification, and radiolabeling of a novel 120-kD surface protein on Blastomyces dermatitidis yeasts to detect antibody in infected patients. J Clin Invest (1990) 1.46
Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin Pharmacol Ther (1994) 1.45
Identification of two germ-tube-specific cell wall antigens of Candida albicans. Infect Immun (1986) 1.43
Kinetics of the antibody response to type III pneumococcal polysaccharide. I. Evidence that suppressor cells function by inhibiting the recruitment and proliferation of antibody-producing cells. J Immunol (1976) 1.42
Marked disparity between trabecular and cortical bone loss with age in healthy men. Measurement by vertebral computed tomography and radial photon absorptiometry. Ann Intern Med (1984) 1.38
Transformation of Rickettsia prowazekii to erythromycin resistance encoded by the Escherichia coli ereB gene. J Bacteriol (2000) 1.38
Transmission of human rotaviruses to gnotobiotic piglets. J Med Microbiol (1975) 1.38
Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol (2008) 1.36
The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol (1986) 1.36
Latex agglutination tests for detection of Candida antigens in sera of patients with invasive candidiasis. J Infect Dis (1986) 1.35
Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther (1982) 1.35
Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther (1992) 1.32
Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res (1971) 1.32
Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol (1984) 1.30
Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res (1999) 1.30
Association of vitro Escherichia coli adherence to vaginal and buccal epithelial cells with susceptibility of women to recurrent urinary-tract infections. N Engl J Med (1981) 1.29
Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav (2009) 1.29
Generation of Tn5 insertions in streptococcal conjugative transposon Tn916. Appl Environ Microbiol (1987) 1.29
Transfer of the conjugal tetracycline resistance transposon Tn916 from Streptococcus faecalis to Staphylococcus aureus and identification of some insertion sites in the staphylococcal chromosome. J Bacteriol (1987) 1.28
Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci (1989) 1.27
Kidney and retinal defects (Krd), a transgene-induced mutation with a deletion of mouse chromosome 19 that includes the Pax2 locus. Genomics (1994) 1.25
Effect of carbohydrates on adherence of Escherichica coli to human urinary tract epithelial cells. Infect Immun (1980) 1.25
Exon organization, coding sequence, physical mapping, and polymorphic intragenic markers for the human neuronal sodium channel gene SCN8A. Genomics (1998) 1.24
Kinetics of antibody responses to cell wall mannan and a major cytoplasmic antigen of Candida albicans in rabbits and humans. J Lab Clin Med (1980) 1.24
5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur J Pharmacol (2000) 1.23
Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther (1997) 1.23
Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. J Cancer Surviv (2012) 1.21
Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation. Eur J Pharmacol (1982) 1.21
Isolation of Campylobacter hyointestinalis from pigs in the United Kingdom. Vet Rec (1984) 1.21
Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology (2008) 1.19
Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol (2000) 1.19
Perceptions of pain relief after surgery. BMJ (1990) 1.19
A single residue, aspartic acid 95, in the delta opioid receptor specifies selective high affinity agonist binding. J Biol Chem (1993) 1.19
Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol (2011) 1.18
Immunologic recognition of a 25-amino acid repeat arrayed in tandem on a major antigen of Blastomyces dermatitidis. J Clin Invest (1993) 1.18
Revisional total hip replacement for failed ring arthroplasty. J Bone Joint Surg Am (1979) 1.18
Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther (1991) 1.18
Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J (Clin Res Ed) (1982) 1.17
An audit of outcome of treatment in acromegaly. Q J Med (1993) 1.17
Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells. J Neuroimmunol (1994) 1.16
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur J Pharmacol (1981) 1.16
Purification and characterization of a major cytoplasmic antigen of Candida albicans. Infect Immun (1981) 1.15
Role of the latex agglutination test for cryptococcal antigen in diagnosing disseminated infections with Trichosporon beigelii. J Infect Dis (1985) 1.14
Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J Med Chem (1998) 1.14
Recovery in malignant hypertension presenting as acute renal failure. Q J Med (1984) 1.13
Neuronal expression of Fig4 is both necessary and sufficient to prevent spongiform neurodegeneration. Hum Mol Genet (2012) 1.13
Analysis of bronchoalveolar lavage specimens from immunocompromised patients with a protocol applicable in the microbiology laboratory. J Clin Microbiol (1988) 1.13
An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther (2012) 1.13
Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem (2000) 1.11
Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J Med Chem (1986) 1.11
Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem (1982) 1.10
Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Eur J Pharmacol (1984) 1.09
Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther (1991) 1.09
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J Med Chem (1985) 1.09
Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl) (1999) 1.08
Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers. J Med Chem (1986) 1.08
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. J Med Chem (2001) 1.08